SHALBY Shalby Q2 FY26 results (Jul–Sep 2025) and concall
Shalby reported a mixed Q2 FY26, showcasing healthy consolidated revenue and EBITDA growth, largely propelled by its MedTech segment's strong performance and turnaround in EBITDA. However, profitability at the consolidated PAT level for H1 and standalone PBT for Q2 saw declines. The Shalby International Hospital continues to struggle with low occupancy and negative EBITDA, while management outlined strategies for hospital occupancy recovery, MedTech profitability, and ongoing capital expenditure in advanced medical technologies.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue up 6.3%, net profit up 250.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 268 | 276 | 265 | 296 | 285 +6% |
| EBITDA | 33 | 34 | 21 | 42 | 42 +27% |
| Net profit | 2 | -3 | -12 | 8 | 7 +250% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
